CD8⁺/FOXP3⁺-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study

References

• Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res 2014; 20:4200-9; PMID:24803583; http://dx.doi.org/10.1158/1078-0432.CCR-13-2574
   PubMed Web of Science ®Google Scholar
• Iwata S, Ishii T, Kawai A, Hiruma T, Yonemoto T, Kamoda H, Asano N, Takeyama M. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol 2014; 21:263-8; PMID:23975321; http://dx.doi.org/10.1245/s10434-013-3210-4
   PubMed Web of Science ®Google Scholar
• Bakhshi S, Radhakrishnan V. Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010; 10:271-87; PMID:20132002; http://dx.doi.org/10.1586/era.09.186
   PubMed Web of Science ®Google Scholar
• Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Neumann A, Korsching E. Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database 2014; PMID:24865352; http://dx.doi.org/10.1093/database/bau042
   PubMedGoogle Scholar
• Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 2010; 16:4256-67; PMID:20610556; http://dx.doi.org/10.1158/1078-0432.CCR-10-0284
   PubMed Web of Science ®Google Scholar
• Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10:205; PMID:23034130; http://dx.doi.org/10.1186/1479-5876-10-205
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013; 171:36-45; PMID:23199321; http://dx.doi.org/10.1111/j.1365-2249.2012.04657.x
   PubMed Web of Science ®Google Scholar
• Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19:217-23; PMID:17306521; http://dx.doi.org/10.1016/j.coi.2007.02.004
   PubMed Web of Science ®Google Scholar
• Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 1992; 34:241-51; PMID:1311218; http://dx.doi.org/10.1007/BF01741792
   PubMed Web of Science ®Google Scholar
• Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 1998; 194:679-84; PMID:9820863; http://dx.doi.org/10.1016/S0344-0338(98)80126-X
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, Cao N, Liu L, Zhang Y. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PloS One 2013; 8:e70689; PMID:23940627; http://dx.doi.org/10.1371/journal.pone.0070689
   PubMed Web of Science ®Google Scholar
• Kunz P, Fellenberg J, Moskovszky L, Sapi Z, Krenacs T, Poeschl J, Lehner B, Szendroi M, Ewerbeck V, Kinscherf R et al. Osteosarcoma microenvironment: whole-slide imaging and optimized antigen detection overcome major limitations in immunohistochemical quantification. PloS One 2014; 9:e90727; PMID:24594971; http://dx.doi.org/10.1371/journal.pone.0090727
   PubMedGoogle Scholar
• Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90; PMID:11821461; http://dx.doi.org/10.1200/JCO.20.3.776
   PubMed Web of Science ®Google Scholar
• Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, Kager L, Kuhne T, Sydes M, Gelderblom H et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 2013; 31:2303-12; PMID:23669227; http://dx.doi.org/10.1200/JCO.2012.43.8598
   PubMed Web of Science ®Google Scholar
• Nathan SS, Healey JH. Demographic determinants of survival in osteosarcoma. Ann Acad Med Singapore 2012; 41:390-9; PMID:23052433
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106:1154-61; PMID:16421923; http://dx.doi.org/10.1002/cncr.21724
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004:286-91; PMID:15577500; http://dx.doi.org/10.1097/01.blo.0000145991.65770.e6
   PubMed Web of Science ®Google Scholar
• Kunz P, Fellenberg J, Moskovszky L, Sapi Z, Krenacs T, Machado I, Poeschl J, Lehner B, Szendroi M, Ruef P et al. Improved survival in osteosarcoma patients with atypical low vascularization. Ann Surg Oncol 2014; 22(2):489-96; http://dx.doi.org/.1245/s10434-014-4001-2
   PubMed Web of Science ®Google Scholar
• Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol 2014; 16:15-23; PMID:24632219; http://dx.doi.org/10.1016/j.coph.2014.02.002
   PubMed Web of Science ®Google Scholar
• Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev 2014; 40:523-32; PMID:24345772; http://dx.doi.org/10.1016/j.ctrv.2013.11.006
   PubMed Web of Science ®Google Scholar
• Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012:704872; PMID:22550423; http://dx.doi.org/10.1155/2012/704872
   PubMedGoogle Scholar
• Franz B, Fritzsching B, Riehl A, Oberle N, Klemke CD, Sykora J, Quick S, Stumpf C, Hartmann M, Enk A et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007; 56:1910-20; PMID:17530636; http://dx.doi.org/10.1002/art.22699
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Haas J, Konig F, Kunz P, Fritzsching E, Poschl J, Krammer PH, Bruck W, Suri-Payer E, Wildemann B. Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PloS One 2011; 6:e17988; PMID:21437244
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, Krammer P, Linderkamp O, Suri-Payer E. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006; 108:3371-8; PMID:16868256; http://dx.doi.org/10.1182/blood-2006-02-005660
   PubMed Web of Science ®Google Scholar
• Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N, Sykora J, Banham AH, Roncador G, Kuhn A et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20:1123-9; PMID:NOT_FOUND; http://dx.doi.org/10.1038/sj.leu.2404182
   PubMed Web of Science ®Google Scholar
• Matsuo T, Shimose S, Kubo T, Mikami Y, Arihiro K, Yasunaga Y, Ochi M. Extraskeletal osteosarcoma with partial spontaneous regression. Anticancer Res 2009; 29:5197-201; PMID:20044636
   PubMed Web of Science ®Google Scholar
• Theoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Redini F, Heymann D. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 2005; 5:123; PMID:16188028; http://dx.doi.org/10.1186/1471-2407-5-123
   PubMed Web of Science ®Google Scholar
• Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS One 2013; 8:e80063; PMID:24244610; http://dx.doi.org/10.1371/journal.pone.0080063
   PubMed Web of Science ®Google Scholar
• Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, Ramqvist T. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PloS One 2012; 7:e38711; PMID:22701698; http://dx.doi.org/10.1371/journal.pone.0038711
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
   PubMed Web of Science ®Google Scholar
• Zeestraten EC, Van Hoesel AQ, Speetjens FM, Menon AG, Putter H, van de Velde CJ, Kuppen PJ. FoxP3- and CD8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer. Cancer Microenviron 2013; 6:31-9; PMID:21732187; http://dx.doi.org/10.1007/s12307-011-0071-x
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-64; PMID:16617117; http://dx.doi.org/10.1073/pnas.0509484103
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911; PMID:19464196; http://dx.doi.org/10.1016/j.immuni.2009.03.019
   PubMed Web of Science ®Google Scholar
• Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, van der Zanden L, de Vries RR, Huizinga TW et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005; 66:13-20; PMID:15620457; http://dx.doi.org/10.1016/j.humimm.2004.05.016
   PubMed Web of Science ®Google Scholar
• Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005; 35:1681-91; PMID:15902688; http://dx.doi.org/10.1002/eji.200526189
   PubMed Web of Science ®Google Scholar
• Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003; 112:1437-43; PMID:14597769; http://dx.doi.org/10.1172/JCI19441
   PubMed Web of Science ®Google Scholar
• Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345-54; PMID:17329235; http://dx.doi.org/10.1093/intimm/dxm014
   PubMed Web of Science ®Google Scholar
• Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007; 123:18-29; PMID:17185041; http://dx.doi.org/10.1016/j.clim.2006.10.014
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37:129-38; PMID:17154262; http://dx.doi.org/10.1002/eji.200636435
   PubMed Web of Science ®Google Scholar
• Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013; 39:949-62; PMID:24238343; http://dx.doi.org/10.1016/j.immuni.2013.10.016
   PubMed Web of Science ®Google Scholar
• Povoleri GA, Scotta C, Nova-Lamperti EA, John S, Lombardi G, Afzali B. Thymic versus induced regulatory T cells – who regulates the regulators? Front Immunol 2013; 4:169; PMID:23818888; http://dx.doi.org/10.3389/fimmu.2013.00169
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013; 13:461-7; PMID:23681097; http://dx.doi.org/10.1038/nri3464
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014; 2:690-8; PMID:24866169; http://dx.doi.org/10.1158/2326-6066.CIR-13-0224
   PubMed Web of Science ®Google Scholar
• Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 2009; 26:1005-12; PMID:19802733; http://dx.doi.org/10.1007/s10585-009-9290-7
   PubMed Web of Science ®Google Scholar
• Park JY, Jang MJ, Chung YH, Kim KY, Kim SS, Lee WB, You S, Choi YS, Hur DY, Kim D. Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB. Int Immunopharmacol 2009; 9:1530-9; PMID:19778641; http://dx.doi.org/10.1016/j.intimp.2009.09.008
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi.org/10.1002/path.4287
   PubMed Web of Science ®Google Scholar
• Bielack S, Whelan J, Marina N, Hook J, Jovic G, Krailo MD, Butterfass-Bahloul T, Kühne T, Eriksson M, Teot LA et al. MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization. J Clin Oncol 2013; 31 ( abstract); PMID:23669227
   PubMed Web of Science ®Google Scholar
• Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-91; PMID:NOT_FOUND; http://dx.doi.org/10.1001/jama.285.15.1987
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7:e1000251; PMID:20352064; http://dx.doi.org/10.1371/journal.pmed.1000251
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012; 9:e1001216; PMID:22675273; http://dx.doi.org/10.1371/journal.pmed.1001216
   PubMed Web of Science ®Google Scholar
• Lin IF, Chang WP, Liao YN. Shrinkage methods enhanced the accuracy of parameter estimation using Cox models with small number of events. J Clin Epidemiol 2013; 66:743-51; PMID:23566374; http://dx.doi.org/10.1016/j.jclinepi.2013.02.002
   PubMed Web of Science ®Google Scholar
• Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. A J Epidemiol 2007; 165:710-8; PMID:17182981; http://dx.doi.org/10.1093/aje/kwk052
   PubMed Web of Science ®Google Scholar
• Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Research 2008; 14:5977-83; PMID:18829476; http://dx.doi.org/10.1158/1078-0432.CCR-07-4534
   PubMed Web of Science ®Google Scholar